KalVista Pharmaceuticals Announces Collaboration with Merck

KalVista Pharmaceuticals, Inc announced that it has entered into a collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for KVD001, the Company investigational intravitreal (IVT) injection.

EAHP Congress – register as a participant and submit your abstract

Gothenburg in Sweden, a beautiful city with an exciting cultural life will be the destination of the 23rd Congress of the EAHP.Hospital pharmacists from all over the world will be gathering from 21st to 23rd March 2018

Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer

Hutchison China MediTech Limited reported preliminary clinical activity, safety, and tolerability data of fruquintinib, an investigational selective inhibitor...

MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris

MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that first patient has been dosed in its pivotal Phase 3 clinical trial assessing the safety and efficacy of MC2-01 Cream ...

GSK receives approval for Benlysta in Japan for the treatment of systemic lupus erythematosus

GSK announced today that the Japanese Ministry of Health, Labour and Welfare has approved Benlysta (belimumab) for the treatment of adult patients...

Batavia Biosciences Expands its Viral Vector and GMP Facilities to Accommodate Increasing Market

Batavia Biosciences announces the expansion of its viral vector process development facilities in the USA and its GMP clean room facilities in the Netherlands...

For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
or
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2017 / Editorial Calender please click here

For the latest visit: www.worldpharmatoday.com